Diabetes and Neurodegeneration in Wolfram Syndrome: A multicenter study of phenotype and genotype by Rohayem, Julia et al.
Diabetes and Neurodegeneration in
Wolfram Syndrome
A multicenter study of phenotype and genotype
JULIA ROHAYEM, MD
1
CHRISTIAN EHLERS, PHD
2
BÄRBEL WIEDEMANN, MSC
3
REINHARD HOLL, MD
4
KONRAD OEXLE, MD
5
OLGA KORDONOURI, MD
6
GIUSEPPINA SALZANO, MD
7
THOMAS MEISSNER, MD
8
WALTER BURGER, MD
9
EDITH SCHOBER, MD
10
ANGELA HUEBNER, MD
1
MIN AE LEE-KIRSCH, MD
1
THE WOLFRAM SYNDROME DIABETES
WRITING GROUP*
OBJECTIVE—Todescribethediabetesphenotype inWolframsyndromecomparedwithtype
1 diabetes, to investigate the effect of glycemic control on the neurodegenerative process, and to
assess the genotype-phenotype correlation.
RESEARCH DESIGN AND METHODS—The clinical data of 50 patients with Wolfram
syndrome-related diabetes(WSD) were reviewedand comparedwiththedata of 24,164patients
withtype1diabetes.PatientswithameanHbA1cduringchildhoodandadolescenceof#7.5and
.7.5% were compared with respect to the occurrence of additional Wolfram syndrome symp-
toms. The wolframin (WFS1) gene was screened for mutations in 39 patients. WFS1 genotypes
were examined for correlation with age at onset of diabetes.
RESULTS—WSDwasdiagnosedearlierthantype1diabetes(5.463.8vs.7.964.2years;P,
0.001) with a lower prevalence of ketoacidosis (7 vs. 20%; P = 0.049). Mean duration of re-
mission in WSD was 2.3 6 2.4 vs. 1.6 6 2.1 in type 1 diabetes (NS). Severe hypoglycemia oc-
curred in 37 vs. 7.9% (P , 0.001). Neurologic disease progression was faster in the WSD group
with a mean HbA1c .7.5% (P = 0.031). Thirteen novel WSF1 mutations were identiﬁed. Pre-
dictedfunctionalconsequence of WFS1 mutationscorrelated with ageatWSDonset(P=0.028).
CONCLUSIONS—Endoplasmicreticulum stress–mediateddecline ofb-cells inWSDoccurs
earlier in life than autoimmune-mediated b-cell destruction in type 1 diabetes. This study
establishes a role for WFS1 in determining the age at onset of diabetes in Wolfram syndrome
and identiﬁes glucose toxicity as an accelerating feature in the progression of disease.
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W
olfram syndrome, also referred
to as DIDMOAD (diabetes insip-
idus, diabetes mellitus, optic at-
rophy, and deafness), is a rare autosomal
recessive syndrome (OMIM #222300)
characterized by juvenile-onset diabetes,
progressive neurologic degeneration, and
endocrine dysfunction. Wolfram syn-
drome is caused by biallelic mutations
of the WFS1 gene encoding wolframin
(1,2), a transmembrane glycoprotein
that localizes in the endoplasmic reticu-
lum (ER). WFS1 has been implicated in
the unfolded protein response, a cellular
stress response induced by the accumula-
tion of unfolded proteins within the ER
lumen, which is pivotal to cellular ho-
m e o s t a s i sa n di n t e g r i t y( 3 , 4 ) .L o s so f
WFS1 function is thought to result in
chronic ER stress–mediated apoptosis of
pancreatic b-cells, neuroendocrine, and
neuronal cells, leading to a progressive
decline of endocrine function and neuro-
degeneration (5).
Clinically, Wolfram syndrome is sus-
pected in a patient presenting with the
minimal criteria of juvenile-onset diabe-
tesandbilateralprogressiveopticatrophy
(6). Additional clinical features include
sensor neuronal hearing loss; neurogenic
bladder; ataxia; dysarthria; dysphagia;
dementia; psychiatric disease; and endo-
crine dysfunction, such as diabetes insip-
idus, hypogonadism, hypothyroidism,
and growth retardation (7–9).
To date, little is known about Wol-
fram syndrome–related diabetes (WSD)
features compared with autoimmune
type 1 diabetes(10),and the contribution
of glycemic control to the observed de-
cline in neurologic and endocrine func-
tion remains undeﬁned. Previous studies
in small patient cohorts have provided
some evidence for a genotype–phenotype
correlation in Wolfram syndrome (11–
13). To gain further insight into the nat-
ural history of Wolfram syndrome, we
conducted a large-scale phenotypic study
of WSD compared with type 1 diabetes,
delineated the role of glycemic control
in disease progression, and examined
genotype–phenotype relationships.
RESEARCH DESIGN AND
METHODS
Patient cohorts and study design
The study enrolled 50 patients with
Wolfram syndrome from 40 families be-
tween 2004 and 2010. Patients were
identiﬁed through the German Diabetes
Prospective Documentation (DPV) data-
base, a nationwide prospective registry that
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ORIGINAL ARTICLEevaluates type 1 diabetes, and inquiries at
scientiﬁc meetings. Overall, 24 centers from
GermanyandSoutheasternEuropeancoun-
tries participated in this study (Wolfram
Syndrome Diabetes Writing Group).
Criteria for patients being included
in the study were juvenile-onset diabetes
and optic atrophy or juvenile-onset di-
abetes and molecular evidence of WFS1
mutations. Detailed clinical and labora-
tory data were recorded by referring
physicians in a standardized question-
naire. Blood samples were taken from a
subset of patients for mutation analysis.
For comparison of WSD with type 1 di-
abetes,dataof24,164patientswithtype1
diabetes aged ,21 years from the DPV
database were used.The localethics com-
mittee approved the study.
Mutation analysis
Thirty-ninepatientswithunknownWFS1
genotype were screened for mutations.
Genomic DNA was extracted from pe-
ripheral blood lymphocytes according to
standard procedures. Exon 1 to 8 of the
WFS1 gene, including ﬂanking intronic
regions, were ampliﬁed by PCR and se-
quenced on an automated sequencer
(ABI 3730, Applied Biosystems, Foster
City, CA). Identiﬁed mutations were
compared with the Human Gene Muta-
tion Database and the WFS1 Gene Muta-
tion and Polymorphism Database of the
Kresge Hearing Research Institute.
Characterization of WSD and
comparison with type 1 diabetes
HbA1c was measured by standardized
methods, as established in the referring
physician’s hospital, and the patient’si n -
dividual mean HbA1c during the obser-
vation period during childhood and
adolescence was determined. Data on
diabetes onset, remission phase, insulin
requirements,glycemiccontrol,andcom-
plications in WSD were compared with
thecorrespondingdataof24,164patients
with type 1 diabetes aged ,21 years from
the DPV database. Differences between
WSD and type 1 diabetes data were statis-
tically analyzed using the one-sample t test
and the Fisher exact test. Normal distribu-
tion was assessed by the Kolmogorov-
Smirnov test.
Analysis of neurodegenerative and
endocrine disease in WSD and
effect of diabetes control on
disease progression
All patients with WSD were examined for
additional symptoms such as diabetes
insipidus, deafness, bladder dysfunction,
neurologic or psychiatric symptoms, pu-
berty disorders, hypogonadism, or thyroid
dysfunction.Theassociationbetweenmean
HbA1cduringchildhoodandadolescence
and the number of Wolfram syndrome
symptoms at ages 10, 11–16, and 17–
21yearswasassessedusingtheSpearman
rank correlation test.
WSD patients were divided into two
groups according to their mean HbA1c
during childhood and adolescence: one
group consisting of probands with a
good control of diabetes, as evidenced
by a mean HbA1c #7.5% and the other
group with a mean HbA1c .7.5%, indic-
ative of a state of chronic hyperglycemia.
Age at onset of additional symptoms of
Wolfram syndrome and their prevalence
were compared in the two groups. Cox
proportional hazard regression analysis,
adjusted for the covariate “age at onset
of WSD,” w a su s e dt oc a l c u l a t et h ep r o b -
ability of any additional Wolfram syn-
drome symptom to appear in the years
after the diagnosis of diabetes, and the re-
sults were plotted as estimated symptom-
free survival function curves.
Genotype–phenotype analysis
Patients were subdivided into the three
categories according to the predicted ef-
fectoftheirWFS1genotype on wolframin
function: 1) mutations with a predicted
complete loss of function, 2)m u t a t i o n s
with a predicted partial loss of function,
and 3) mutations with a putative minor
loss of function. Age at onset of diabetes
was compared among these groups using
ANOVA.
RESULTS
Characterization of WSD and
comparison with type 1 diabetes
The phenotypic characteristics of the
WSD cohort compared with the data of
24,164 patients with type 1 diabetes from
the DPV database are summarized in
Table 1.
The initial manifestation of Wolfram
syndrome was diabetes in 43 patients
(86%), hearing loss in 4 (8%), and optic
atrophy in 3 (6%). All but four patients
were treated with insulin from the time of
diagnosis of diabetes.
WSD was diagnosed earlier than type
1 diabetes (5.4 6 3.8 vs. 7.9 6 4.2 years;
P , 0.001), with a lower prevalence of
ketoacidosis (7 vs. 20.3%; P = 0.049).
Autoantibodies were less often positive
(10 vs. 86%; P , 0.001). Mean duration
of remission was longer (2.3 6 2.4 vs.
1.6 6 2.1 years; P = 0.064 NS). Severe
hypoglycemia occurred at a higher fre-
quencyinWSD(37vs.7.9%;P,0.001).
As calculated from the German data-
set, the prevalence of Wolfram syndrome
in children and adolescents aged ,21
years in Europe is 33/17,000,000
(;1:500,000). The prevalence of WSD
among children and adolescents aged
,21 years with diabetes is 33/24,000
(;1:730).
Neurodegenerative disease in WSD
and effect of diabetes control on
disease progression
Age at onset and the prevalence of addi-
tional Wolfram syndrome symptoms in
ourpatientcohortarereportedinTable2.
In 74% of the patients, optic atrophy was
theﬁrstneurodegenerativesymptomafter
diabetes onset. Patients with atonic blad-
der had urinary tract dilation and/or re-
current renal tract infections. Neurologic
symptoms included learning difﬁculties
(24%), coordination deﬁcits (16%), ataxia
(12%), dysarthria or aphasia (8%), elec-
troencephalograph abnormalities (6%),
mental or motor retardation (6%), and
dysphagia (4%). Magnetic resonance im-
aging showed cortical atrophy in 18%.
Symptoms of hypo- or hypergonado-
tropic hypogonadism occurred in 34%,
including late puberty or pubertal arrest,
abnormalities in menstrual bleeding, tes-
ticular atrophy with testosterone deﬁ-
ciency, and erectile dysfunction.
Sudden and complete loss of visual
acuity was observed in one patient after
prolonged severe hypoglycemia. Acute
neurologic deterioration occurred in one
patient after a severe febrile infection and
in one patient after general anesthesia
during the second decade of life. In all
patients, this acute disease progression
was partially reversible over time.
A correlation was found between the
numberofWolfram syndromesymptoms
and the patient’s mean HbA1c during
childhoodandadolescence.Inthepatient
group, observed until the age of 17 to 21
years, this correlation was statistically sig-
niﬁcant (Spearman rank correlation co-
efﬁcient, 0.485; P = 0.012).
The prevalence of diabetes insipidus,
deafness,andneurologicand psychologic
symptoms was lower, and the time of
symptom-free survival for each of these
additional Wolfram syndrome symp-
toms after diagnosis of WSD was higher,
in the well-controlled WSD group with
a mean HbA1c #7.5 vs. .7.5%. This is
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Phenotype and genotype in Wolfram syndrome–related diabetessummarized in Table 2 and illustrated in
Supplementary Fig. A1. Owing to the rel-
atively small numbers of patients in each
symptom-speciﬁc category, statistical sig-
niﬁcancewasreachedonlyinonecategory
(psychologic symptoms) and in an analy-
sis with all symptoms pooled (P = 0.031).
No correlation was found concerning in-
sulin usage (IU/kg/body weight) and
HbA1c (Supplementary Fig. A2).
Genotype–phenotype analysis
Among 39 patients screened for WFS1
mutations, 34 mutations were detected,
13 of which were novel (Table 3). The
mutational spectrum included missense,
nonsense, and splice site mutations as
well as smaller deletions and insertions,
which were commonly associated with a
shift of the WFS1 reading frame. Most
mutations were located within exon 8
of the WFS1 gene, which encodes the
COOH-terminal extracellular part of
wolframin at the luminal site of the ER
membrane.
Mutations were divided into three
categories according to the predicted
functional consequences on wolframin
function (Fig. 1). Assuming that Wolfram
syndrome results from a loss of WFS1
function, patients were grouped as follows:
c Group 1: individuals carrying muta-
tions with a predicted complete loss
of function, including N-terminal non-
sense and frameshift mutations;
c Group 2: individuals carrying muta-
tions with a predicted partial loss of
function, including COOH-terminal
nonsense and frameshift mutations or
small in-frame deletions and individuals
compound heterozygous for a predicted
complete and partial loss of function
mutation; and
c Group 3: individuals carrying muta-
tions with a putative minor loss of
function, including missense mutations
and individuals compound heterozy-
gous for a predicted partial and minor
loss of function mutation (Fig. 1).
Comparison of age at onset of WSD
among these groups revealed signiﬁcant
differences (ANOVA, P = 0.028). Thus,
mean age at WSD onset was 3.7 6 1.7
years in individuals carrying mutations
with a predicted complete loss of func-
tion, 5.8 6 2.6 years in those carrying
mutations with a predicted partial loss
of function, and 7.5 6 6.0 years in
Table 1—Diabetes phenotypes in patients with WSD and type 1 diabetes
n
Frequency
occurrence (%) Mean (SD)
Median
(range)
Median (lower–upper
quartile) P
Age at onset of diabetes (years)
WSD 50 5.4 (3.8) 4.3 (1–17) ,0.001*
Type 1 diabetes 24,164 7.9 (4.2) 7.7 (4–11)
Ketoacidosis pH ,7.3 at diabetes manifestation
WSD 41 7 0.049†
Type 1 diabetes 13,644 20.3
Autoantibodies against b-cell elements
WSD 31 10 ,0.001†
Type 1 diabetes 11,144 86
HbA1c (%) at diagnosis of diabetes
WSD 29 10.6 (2.9) 10.0 (5.8–16) 0.436*
Type 1 diabetes 23,850 11.0 (2.4) 10.8 (9.3–12.5)
Remission (years)‡
WSD 33 2.3 (2.4) 2.0 (0–8.5) 0.064*
Type 1 diabetes 10,195 1.6 (2.1) 0.8 (0.4–1.7)
Insulin requirements (IU/kg/day)
WSD 46 (0.46–0.9)
Type 1 diabetes 24,018 0.81 (0.3) 0.79 (0.6–1.0)
HbA1c (%)
WSD 47 7.9 (1.4) 7.8 (5–12) 0.064*
Type 1 diabetes 23,850 8.0 (1.7) 7.6 (6.9–8.7)
Diabetic ketoacidosis after insulin substitution
WSD 41 7 0.427†
Type 1 diabetes 23,504 4.4
$1 severe hypoglycemia during childhood/adolescence
WSD 38 37 ,0.001†
Type 1 diabetes 22,324 7.9
Persistent microalbuminuria
WSD 50 0 0.005†
Type 1 diabetes 15,547 11.1
Diabetic retinopathy
WSD 50 0 ,0.001†
Type 1 diabetes 12,096 0.6
Meanage(years)atthetimeofdataacquisitionwas18.1forWSDand11.9fortype1diabeticpatients.Themeantime(years)ofobservationfromthetimeofdiagnosis
ofdiabetes was12.6forWSD and 4.0fortype1diabetes.n,numberof patientsexamined.*Onesample ttest:P.0.05isNS.†Fisher exact:P.0.05is NS. ‡Insulin
,0.5 IE/kg/day, HbA1c ,7.5%.
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Rohayem and Associatesindividuals carrying mutations with a pu-
tative minor loss of function (Fig. 1).
CONCLUSIONS—This is the ﬁrst
study characterizing WSD in a large Eu-
ropean cohort of patients in comparison
with a nationwide cohort of patients with
type 1 diabetes. We demonstrated that
WSD occurs earlier in life than type 1
diabetes.Thismay be because the process
of ER stress–mediated b-cell decline in
WSD already starts at the beginning of
life, whereas autoimmune-mediated
b-cell destruction in type 1 diabetes is
triggered later. In addition to b-cell loss,
insulin secretion has been shown to be
impaired in wfs1 knockout mice (14).
Thus, defective insulin secretion may
contribute to the early diabetes onset in
WSD. In line with previous reports, WSD
was autoantibody-negative and not com-
monly complicated by ketoacidosis in
our cohort (6,15). Although the differ-
ences in remission period and insulin
requirement between the WSD and type 1
diabetes groups did not reach statistical
signiﬁcance, a high degree of variability
was noted in these features among pa-
tients with WSD. Some WSD patients
showed a remarkably long remission pe-
riod of .8 years or an insulin require-
ment of ,0.5 IU/kg/day. Similarly,
Fishman et al. (16) described Wolfram
syndrome patients with measurable
C-peptide 8 years after diabetes onset,
and Cano et al. (10) reported that the
daily insulin requirement and mean
HbA1c were lower in WSD than in type 1
diabetes. These ﬁndings suggest that pro-
gression of diabetes toward total insulin
deﬁciency may be slower in WSD than
in type 1 diabetes. Thus, WSD might be
considered if diabetes occurs without
diabetic ketoacidosis in a preschool child
with negative autoantibodies and a strik-
ingly long remission period.
In addition, we noted that severe hy-
poglycemia occurred at a higher frequency
in patients with WSD than with type 1
diabetes. This was not caused by corti-
sol deﬁciency and may be explained
by impairment of hypoglycemia aware-
ness as a result of neurologic dysfunc-
tion.
We also observed that transient se-
vere glucose deprivation in patients with
WSD was accompanied by an acute,
partially reversible, neurologic or visual
deterioration. Hypoglycemia is known to
perturb ER function (5).Thisshouldurge
professionalandfamilycaretakerstocare-
fullyadjustinsulintherapyinstrictavoid-
ance of hypoglycemic events. Our data
also conﬁrm a decreased prevalence of
microvascular complications in WSD, as
reported previously (10,15). This is an
intriguing ﬁnding because hyperglyce-
mia occurs on top of tissue ER stress in
Wolfram syndrome. Although the under-
lying molecular mechanisms remain to be
investigated, this may suggesta protective
effect of wolframin deﬁciency on the
Table 2—Symptoms of Wolfram syndrome: age at onset, prevalence, and symptom-free survival with regard to glucose control in WSD
Optic atrophy Diabetes insipidus Deafness
Bladder
dysfunction
Neurologic
problems
Psychologic
problems
Mean (range) Mean (range) Mean (range) Mean (range) Mean (range) Mean (range)
Age in years at symptom onset
All patients 9 (2–18) 13 (5–22) 10 (1–20) 15 (1–22) 11 (1–22) 14 (8–20)
Patients with a mean
HbA1c #7.5% 9 (4–18) 13.5 (5–18) 6 (1–18) 16 (1–22) 10 (1–22) 14.5 (14–15)
Patients with a mean
HbA1c .7.5% 9 (2–17) 11 (5.5–22) 11 (1–18) 13.5 (7–18) 11 (4–19) 14 (8–20)
%%% %%%
Prevalence of symptoms
All patients 92 52 68 48 62 34
Patients with a mean
HbA1c #7.5% 94.7 31.6 58 47.4 42.1 10.5
Patients with a mean
HbA1c .7.5% 89.2 64.3 75 50 75 53.6
Median
(95% CI)
Median
(95% CI)
Median
(95% CI)
Median
(95% CI)
Median
(95% CI)
Median
(95% CI)
Symptom-free survival in years
after WSD diagnosis*
All patients 4.7 (3.2–6.2) 13 (9.7–16.3) 9.8 (7.4–12.2) 14.0 (12.1–15.9) 9.9 (6.4–13.4) 14 (10.2–17.8)
Patients with a mean
HbA1c #7.5% 2.2 (0.8–3.6) 16.7 (8.21–25.2) 9.8 (0.8–18.8) 11.9 (9.4–14.4) 20.7 (—) —
Patients with a mean
HbA1c .7.5% 5.2 (4.6–5.8) 13 (6.6–20.4) 8.9 (6.3–11.5) 14 (11.8–16.2) 8 (4.7–11.8) 12.3 (10.7–13.8)
PPP PPP
Signiﬁcance of differences
Each individual symptom 0.349 0.115 0.865 0.841 0.089 0.033
All symptoms† 0.031 0.031 0.031 0.031 0.031 0.031
*Cox regression. †The symptom-free survival of all neurodegenerative symptoms pooled in Wolfram syndrome is signiﬁcantly different (P 5 0.031) in patients with
am e a nH b A 1c higher than 7.5%, compared with patients with a mean HbA1c lower than or equal to 7.5%.
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The ER is the cell organelle where
secretory proteins are folded. Accumula-
tion of unfolded or misfolded proteins
causesERstressandinducestheunfolded
protein response (UPR), a signaling net-
work that aims at restoring ER homeosta-
sis by halting protein translation and
activating molecular chaperones involved
in protein folding (17). However, if ER
stress persists, the UPR shifts from a
survival-promoting to a proapoptotic
pathway, thereby ensuring proper dis-
posal of irreversibly damaged cells.
Wolframin is a UPR component and
promotes cell survival by mitigating ER
stress signaling. Deﬁciency of wolframin
caused by mutations in the WFS1 gene
leads to an inadequate activation of the
UPR in response to accumulation of un-
folded proteins within the ER lumen, es-
pecially in tissues with high secretory
demands (18), which results in apoptotic
cell death (5). In patients with Wolfram
syndrome, these mechanisms underlie
progressiveneurodegenerationandendo-
crine dysfunction. In fact, ER stress–
induced b-cell loss and atrophy of the
islets of Langerhans have been shown to
cause infancy-onset WSD (18,19).
Consistent with previous reports,
diabetes was the ﬁrst manifestation of
Wolfram syndrome in most patients in
this study. An intriguing observation was
a positive correlation between a high mean
HbA1c and the number of neurodegener-
ative and endocrine symptoms that oc-
curred after the onset of WSD. This
Figure 1—A: A schematic presentation of the wolframin protein and analysis of genotype-genotype correlation shows the relative positions of
WFS1mutationswithinthewolframinpolypeptidechainwiththeﬁvetransmembranedomainsindicated(adaptedfromGeneReviews,Universityof
Washington, Seattle, WA). Mutations are color-coded according to their mutation categories: group 1 (red), group 2 (blue), and group 3 (green).
Unclassiﬁable variants are indicated in black; novel mutations are indicated in boldface. B:G e n o t y p e –phenotype correlation; the differences in
mean age at WSD onset between group 1 (3.7 6 1.7 years), 2 (5.8 6 2.6 years), and 3 (7.5 6 6.0 years) are signiﬁcant (ANOVA, P =0 . 0 2 8 ) .
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Phenotype and genotype in Wolfram syndrome–related diabetesindicates that ER stress due to wolframin
deﬁciency may only partially account for
disease progression after the onset of
WSD. Because additional Wolfram syn-
drome symptoms are more likely to de-
velop in patients with poor glycemic
control, hyperglycemia may be involved
as well. The deleterious effects of glucose
on tissues, collectively described as glu-
cose toxicity, involve oxidative stress by
reactive oxygen species (20,21). Antioxi-
dantenzymeactivitiesinLangerhansislets
arerelativelylowcompared withothertis-
sues (3,20). In patients with type 2 diabe-
tes, high glucose concentrations impair
expression and secretion of insulin in
b-cells and accelerate apoptosis of islet
cells (22,23). These observations may ex-
plain why the duration of residual b-cell
function after onset of WSD showed ex-
treme variations. Our study provides
evidence that wolframin-deﬁcient subjects
with infancy-onset and poorly controlled
diabetes experience a faster progression of
neurodegenerative disease than those with
gooddiabetescontrol.Fromtheseﬁndings,
we hypothesize that ER stress in patients
with WSD is enhanced by additional
chronic oxidative stress resulting from
chronic hyperglycemia. Hence, tissues
with high wolframin expression would be
put in double jeopardy, and the process of
cell death would be accelerated. This un-
derscores the importance of good diabetes
control inWolfram syndrome to retardthe
neurologic and endocrine degenerative
course of the disease.
We also observed in individual pa-
tients that febrile infections and general
anesthesia may induce acute neurologic
deterioration in Wolfram syndrome, in-
dicating that these conditions may con-
stitute an additional source of ER stress
enhancement. Oxidative stress is also in-
ducible by cytokine storm (3). High-fat
diet, amino acid starvation, environmen-
tal toxins, hypoxia, or radiation are other
oxidative stressors (3,5,24). Knowledge
of these ER stress-enhancing factors may
be important in the clinical management
of patients with Wolfram syndrome.
In our cohort, we identiﬁed 34 WFS1
mutations, including 13 distinct previ-
ously unreported mutations, expanding
the spectrum of known mutations in
Wolfram syndrome. We aimed at deter-
mining the relationship between geno-
type and phenotype by dividing patients
intothreegroupsaccordingtothepredic-
ted consequences of their mutations on
wolframin function and assuming trans-
lation of mutated WSF1 transcripts, as
previously shown (25). Using this ap-
proach, we showed genotype–phenotype
correlation suggesting a role for WFS1
in determining the age at onset of WSD.
This is in line with the data from a meta-
analysis by Cano et al. (13) showing that
thepresenceoftwoinactivatingmutations
predisposestoanearlieronsetofdiabetes
and optic atrophy. However, validation of
any genotype–phenotype correlation must
await detailed functional analysis of muta-
tions on a cellular and molecular level.
Taken together, we demonstrated
that ER stress–mediated decline of
b-cells in WSD occurs earlier in life than
autoimmune-mediated b-cell destruction
in type 1 diabetes, that poor glycemic con-
trol is associated with a faster progression
of neurodegeneration, and that WFS1-
mutations inﬂuence the age at onset of
WSD. Because ER stress has been recog-
nized as contributing to insulin resistance
in type 2 diabetes (5,22), the dissection of
pathogenic mechanisms in monogenic ER
stress–mediated b-cell loss may also con-
tribute to the understanding of type 2
diabetes pathogenesis.
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